PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 20, 2025Aesthetic Surgery Journal Open Forum2 citationsOpen Access

Findings From the Great British and Northern Ireland Botulinum Toxin Survey: Treatment Outcomes, Patient Experience and Regulations From a Cross-Sectional Survey

View Full Paper
LSLee SmithJLJosé Francisco López‐GilJGJulia Gawronska

Key Points

  • A significant 66% of respondents reported their botulinum toxin treatment was given by a licensed prescriber, indicating varying practitioner reliability.
  • Acute complications like bruising (26.1%) and headaches (24.7%) were prevalent among participants, while longer-term issues included nerve damage (2.5%).
  • The national survey engaged 919 participants and uncovered notable gaps in informed consent and complication support during cosmetic botulinum toxin treatments.
  • Stronger regulations were supported by 57.8% of participants, highlighting concerns over inconsistent practice and treatment oversight.

Abstract

Abstract Background Given rising demand for Botulinum toxin (BoNT) treatments and limited data on safety, ethics, and regulation, a national survey explored experiences with cosmetic BoNT in the United Kingdon (UK). Objectives To conduct a national observational survey with the aim to capture real-world experiences of cosmetic BoNT in the UK. Methods A cross-sectional online survey gathered data on experiences with cosmetic BoNT injections across the UK. Participation was open to adults (≥18 years) who had received cosmetic BoNT treatment. Results A total of 919 participants completed the survey and were predominantly female, white, and had a high household income. Commonly reported acute complications were bruising/swelling (26.1%), and headache (24.7%). Commonly reported long-term complication were BoNT resistance (2.9%), social withdrawal (2.7%), nerve damage (2.5%), and dry eyes/vision problems (2.5%). In total, 66% stated their treatment was administered by a prescriber, 28% said it was not. Among those treated by a non-prescriber, 40% reported that a prescriber was present during the consultation, 42% said no prescriber was present, and 17% were unsure. Surprisingly a few had not signed a consent form (8%), 11% were not informed of treatment risks and 18% were not told how to respond to complications. A large majority expressed support for enhanced oversight, with 57.8% favouring significantly stricter regulation, and 31.3% somewhat stricter regulation. Conclusions Cosmetic BoNT can offer high satisfaction and a favourable safety profile when administered appropriately. However, findings highlight key vulnerabilities: inconsistent practitioner qualifications, gaps in informed consent, insufficient complication support, and weak regulation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Smith et al. (2025) studied this question.

synapsesocial.com/papers/68d46aa631b076d99fa6760ahttps://doi.org/10.1093/asjof/ojaf115
Ask AI
Helpful
Bookmark
Share
View Full Paper